Standout Papers

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbe... 1990 2026 2002 2014 4.2k
  1. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes (2001)
    Edmund J. Lewis, Lawrence G. Hunsicker et al. New England Journal of Medicine
  2. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (2013)
    Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine
  3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2018)
    Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet
  4. Type 2 diabetes mellitus (2015)
    Ralph A. DeFronzo, Ele Ferrannini et al. Nature Reviews Disease Primers
  5. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ (1990)
    F. Zurlo, Stephen Lillioja et al. American Journal of Physiology-Endocrinology and Metabolism
  6. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial (2014)
    Benjamin M. Scirica, Eugene Braunwald et al. Circulation
  7. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus (2019)
    Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation
  8. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020)
    Thomas A. Zelniker, Marc P. Bonaca et al. Circulation
  9. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum (2017)
    William T. Cefalu, Sanjay Kaul et al. Diabetes Care
  10. Overview of oxidative stress and inflammation in diabetes (2024)
    Itamar Raz et al. Journal of Diabetes
  11. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations (2024)
    Aeron Small, Giorgio Melloni et al. JAMA Cardiology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 110 standout
Sub-graph 1 of 11

Citing Papers

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024 Standout
Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management
2023 Standout

Works of Itamar Raz being referenced

Type 2 diabetes mellitus
2015 Standout
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
2001 Standout

Author Peers

Author Last Decade Papers Cites
Itamar Raz 14772 6002 5439 6237 370 25.1k
Vivian Fonseca 14726 5986 5728 4549 458 25.7k
Robert J. Heine 14784 4550 4668 6164 321 27.8k
Neil R Poulter 15008 4553 8727 15239 439 33.8k
Michel Marre 8347 3848 3239 3658 419 16.6k
Per‐Henrik Groop 9480 5730 4289 3658 519 22.4k
Rury R. Holman 28999 10634 9037 5597 347 39.3k
Johannes F.E. Mann 13170 4920 5887 10175 275 28.7k
Antonio Ceriello 16441 7497 5466 5174 479 34.9k
George L. King 7068 12446 3929 4841 271 31.8k
Lawrence A. Leiter 22573 9257 13843 7456 535 38.1k

All Works

Loading papers...

Rankless by CCL
2026